Fatty liver desease. Nonalcoholic fatty liver disease (NAFLD)
Conditions
Interventions
Intervention 1: The case group receives Dava Al-balgham tablets two pills with each meal, for three months. Intervention 2: The control group receives cellulose tablets in two tablets each serving fo
Treatment - Drugs
The case group receives Dava Al-balgham tablets two pills with each meal, for three months.
The control group receives cellulose tablets in two tablets each serving for three months.
Sponsors
Vice chancellor for research, Qom University of Medical Sciences
Eligibility
Sex/Gender
All
Age
17 Years to 64 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Non-Alcohol-Fatty Liver Detection (NAFLD-Based Ultrasonography) 2- Serum Liver Enzyme Levels above Normal 3- Age between 18 and 65 years. 4- Fill in the consent form for participation in the plan. Exclusion criteria: 1. Patient's lack of consent to continue participating in the project. 2. Any allergy to the drug. 3. The occurrence of any new liver disease that requires the use of specific liver medicines. 4. Pregnancy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ast. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.;Alt. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.;Alkp. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Crt. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;BUN. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;PT. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;PTT. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;INR. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;Level of quality of life. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Questionnaire 36 questions.;BMI. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Weight/(height(meter))2 Kg/m2.;WHR. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Waist to hip circumference Cm/cm.;Blood presure. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Mercury pressure meter mmHg. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Moradi
Faculty of Traditional Iranian Medicine Qom
Outcome results
None listed